Pharmacokinetic Effect of Ketoconazole on Solifenacin in Healthy Volunteers
Authors:
- 7 July 2006
- journal article
- clinical trial
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 99 (1) , 33-36
Abstract
Solifenacin succinate (YM905) is a new, once-daily, orally administered muscarinic receptor antagonist designed to treat overactive bladder. The metabolism of solifenacin involves hepatic cytochrome P450 (CYP) 3A4; therefore, the pharmacokinetics of solifenacin may be affected by drugs that inhibit CYP3A4. This study aimed to examine the effects of co-administration of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of solifenacin in healthy volunteers. In a single-site, open-label, monosequence, crossover study, 17 healthy men and women aged 18 to 65 years received a single 10 mg oral dose of solifenacin, which is is the highest available dose. After a 14-day wash-out period, they began 20 days of oral ketoconazole at a dose of 200 mg once daily. A single 10 mg dose of solifenacin was administered again on day 7 of ketoconazole treatment. Pharmacokinetics was assessed using the standard measurements of maximum plasma concentration (Cmax), time to Cmax, area under the curve (AUC), and elimination half-life (t1/2). Co-administration of ketoconazole resulted in a 1.43 times increase in the C(max) of solifenacin and an approximately 2 times increase in AUC. The mean t1/2 of solifenacin was extended from 49.3 to 77.5 hr whereas time to Cmax did not change. No substantial increase in the overall rate of adverse events, and no significant effects on vital signs, electrocardiography, clinical laboratory values, or physical examinations were noted. Administration of 200 mg ketoconazole once daily in healthy male volunteers resulted in a 2 times increase in exposure of a single 10 mg dose of solifenacin. Since ketoconazole is one of the strongest inhibitors of CYP3A4, it is expected that co-administration of other CYP3A4 inhibitors will not result in a stronger increase in solifenacin exposure.Keywords
This publication has 9 references indexed in Scilit:
- Effect of age on the pharmacokinetics of solifenacin in men and womenInt. Journal of Clinical Pharmacology and Therapeutics, 2005
- Pharmacokinetics and Safety of Solifenacin Succinate in Healthy Young MenThe Journal of Clinical Pharmacology, 2004
- Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trialBritish Journal of Clinical Pharmacology, 2004
- Solifenacin Demonstrates High Absolute Bioavailability in Healthy MenDrugs in R&D, 2004
- Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding studyBJU International, 2003
- Testosterone Supplementation Therapy for Older Men: Potential Benefits and RisksJournal of the American Geriatrics Society, 2003
- M 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary glandNaunyn-Schmiedeberg's Archives of Pharmacology, 2002
- Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discoveryJournal of Pharmacological and Toxicological Methods, 2001
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000